Evidence map›Paper›PMID 30830789›Full record

ArticleMolecular pharmaceutics2019

Impact of Ferroquine on the Solubilization of Artefenomel (OZ439) during in Vitro Lipolysis in Milk and Implications for Oral Combination Therapy for Malaria.

Malinda Salim, Jamal Khan, Gisela Ramirez, Mubtasim Murshed, Andrew J Clulow, Adrian Hawley, Hanu Ramachandruni, Stephane Beilles, Ben J Boyd

Open access · hybridAbstract read
In one paragraph

Article in Molecular pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Small-volumeInternational journal of pharmaceutics: X · 2022
    Article
  7. Fighting Plasmodium chloroquine resistance with acetylenic chloroquine analogues.International journal for parasitology. Drugs and drug resistance · 2022
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. ACS infectious diseases · 2020
    Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Malinda SalimDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences , Monash University (Parkville Campus) , 381 Royal Parade , Parkville , VIC 3052 , Australia.
Jamal KhanDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences , Monash University (Parkville Campus) , 381 Royal Parade , Parkville , VIC 3052 , Australia.
Gisela RamirezDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences , Monash University (Parkville Campus) , 381 Royal Parade , Parkville , VIC 3052 , Australia.
Mubtasim MurshedDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences , Monash University (Parkville Campus) , 381 Royal Parade , Parkville , VIC 3052 , Australia.
Andrew J ClulowDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences , Monash University (Parkville Campus) , 381 Royal Parade , Parkville , VIC 3052 , Australia.ORCID 0000-0003-2037-853X
Adrian HawleySAXS/WAXS Beamline , Australian Synchrotron , ANSTO, 800 Blackburn Road , Clayton , VIC 3169 , Australia.
Hanu RamachandruniMedicines for Malaria Venture , 20, Route de Pré-Bois , 1215 Geneva 15 , Switzerland.
Stephane BeillesSanofi R&D , 371 Rue du Professeur Blayac , 34080 Montpellier , France.
Ben J BoydDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences , Monash University (Parkville Campus) , 381 Royal Parade , Parkville , VIC 3052 , Australia.ORCID 0000-0001-5434-590X
Monash University · AUAustralian Nuclear Science and Technology Organisation · AUMedicines for Malaria Venture · CHSanofi (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Milk is an attractive lipid-based formulation for the delivery of poorly water-soluble drugs to pediatric populations. We recently observed that solubilization of artefenomel (OZ439) during in vitro intestinal lipolysis was driven by digestion of triglycerides in full-cream bovine milk, reflecting the ability of milk to act as an enabling formulation in the clinic. However, when OZ439 was co-administered with a second antimalarial drug, ferroquine (FQ) the exposure of OZ439 was reduced. The current study therefore aimed to understand the impact of the presence of FQ on the solubilization of OZ439 in milk during in vitro intestinal digestion. Synchrotron small-angle X-ray scattering was used for in situ monitoring of drug solubilization (inferred via decreases in the intensity of drug diffraction peaks) and polymorphic transformations that occurred during the course of digestion. Quantification of the amount of each drug solubilized over time and analysis of their distributions across the separated phases of digested milk were determined using high-performance liquid chromatography. The results show that FQ reduced the solubilization of OZ439 during milk digestion, which may be due to competitive binding of FQ to the digested milk products. Interactions between the protonated FQ-H

Indexed as

Drug Delivery SystemsLipolysisAdamantaneAdministration, OralAminoquinolinesAnimalsAntimalarialsBiological AvailabilityFerrous CompoundsHumansIn Vitro TechniquesMalariaMetallocenesMilkPeroxidesSolubilityAdamantaneAminoquinolinesAntimalarialsartefenomelferroquineFerrous CompoundsMetallocenesPeroxidesantimalarialin vitro digestionlipid-based formulationmilkpolymorphismpoorly water-soluble drugsolubilizationX-ray scattering

Identifiers

PMID30830789
PMCPMC6448114
OpenAlexW2920711287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.